

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生物 科技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO WINDING UP PETITION

Reference is made to the announcement of the Company dated 25 October 2023 (the “**Announcement**”) in relation to a winding-up petition filed against the Company. Terms used herein shall have the same meanings as defined in the Announcement unless otherwise stated.

EFFECT OF THE PETITION UNDER THE APPLICABLE LAWS AND REGULATIONS

Pursuant to section 182 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance, in a winding-up by the court, any disposal of property of the company (including things in action), and any transfer of shares, or alteration in the status of the members of the company, made after the commencement of the winding up, shall, unless the court otherwise orders, be void. Any disposition made on or after 29 September 2023 will not be affected if the Petition is subsequently struck out, dismissed or permanently stayed, and hence the Board wishes to remind its shareholders (“**Shareholders**”) and potential investors that, the transfer of the shares in the Company made on or after 29 September 2023 would be void without a validation order from the Court in the event that the Company is ultimately wound up.

The Company wishes to remind Shareholders and potential investors of the risk that the shares of the Company (“**Shares**”), may be restricted as the deposits of the Shares into Central Clearing and Settlement System (“**CCASS**”), may be suspended due to the Petition.

Pursuant to the circular (ref no. CD/DNS/CCASS/332/2016) dated 28 December 2016 issued by Hong Kong Securities Clearing Company Limited (“**HKSCC**”) in relation to the transfer of the shares of listed issuers in respect of which a winding-up petition is presented, after the winding-up petition has been presented, the transfer of shares made thereafter may be void without a validation order from the court. In view of the restrictions and the uncertainties that may arise in relation to the transfer of shares of the affected listed issuers, HKSCC may at any time, and without notice, exercise its powers under the General Rules of the CCASS to temporarily suspend any of its services in respect of the shares of the affected listed issuers. This may include the suspension of acceptance of deposits of share certificates of the affected listed issuers into the CCASS. The share certificates of the affected listed issuers received by HKSCC but not yet re-registered in HKSCC Nominees Limited’s name will also be returned to the relevant CCASS participant and HKSCC shall reserve the right to reverse any credit granted to such CCASS participant by debiting the relevant securities of the affected listed issuers from its CCASS account accordingly. These measures would generally cease to apply from the date when the winding-up petition has been struck out, dismissed or permanently stayed, or the affected listed issuer has obtained the necessary validation order from the relevant court(s).

ACTION TO BE TAKEN IN RELATION TO THE PETITION

In view of the impact of the possible winding-up order on the transfer of shares, the Company is also in the course of seeking advice from its legal advisers for application to the High Court of Hong Kong for a validation order.

Shareholders should note that the Company does not warrant that a validation order will be granted by the High Court of Hong Kong and that any application made by the Company for a validation order may or may not be successful. In addition, any validation order granted by the High Court of Hong Kong may also be subject to conditions.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in securities of the Company.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Executive Director

Hong Kong, 27 October 2023

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and two independent non-executive Directors, namely Ms. Hong Ting and Mr. Wan Bo.